BioCentury
ARTICLE | Clinical News

Celgosivir: Phase II data

November 13, 2006 8:00 AM UTC

In an open-label Phase II trial in 57 patients, celgosivir plus pegylated peginterferon alfa-2b and ribavirin was safe and well tolerated. The trial included 36 non-responders and 21 partial responder...